The immediate effects of cervical spine manipulation on pain and biochemical markers in females with acute non-specific mechanical neck pain: a randomized clinical trial

E.B. Lohman, G.R. Pacheco, L. Gharibvand, N. Daher, K. Devore, G. Bains, M. AlAmeri, and L.S. Berk

School of Allied Health Professions, Physical Therapy Department, Loma Linda University, Loma Linda, CA, USA; School of Allied Health Professions, Allied Health Studies Department, Loma Linda University, Loma Linda, CA, USA; School of Medicine, Department of Pathology and Human Anatomy, Loma Linda University, Loma Linda, CA, USA

ABSTRACT

Study Design: Randomized clinical trial with pre-test, post-test control group design.

Objectives: To examine the immediate effects of cervical spinal manipulation (CSM) on serum concentration of biochemical markers (oxytocin, neurotensin, orexin A, and cortisol).

Background: Several studies have found an association between spinal manipulation (SM) and pain perception. However, the mechanism by which SM modulates pain remains undefined.

Methods: Twenty-eight female subjects with non-specific mechanical neck pain were randomly assigned to one of two interventions (CSM versus sham CSM). Blood samples were drawn before and immediately after the respective interventions. Oxytocin, neurotensin, orexin A, and cortisol were measured from the blood and serum using the Milliplex Map Magnetic Bead Panel Immunoassay on the Luminex 200 Platform.

Results: In the CSM group, there were significant increases in pre- versus post-manipulation mean oxytocin (154.5 ± 60.1 vs. 185.1 ± 75.6, p = .012); neurotensin (116.0 ± 26.5 vs.136.4 ± 34.1, p < .001); orexin A (52.2 ± 31.1 vs. 73.8 ± 38.8, p < .01) serum concentration; but no significant differences in mean cortisol (p = .052) serum concentration. In the sham group, there were no significant differences in any of the biomarkers (p > .05).

Conclusion: The results of the current study suggest that the mechanical stimuli provided through a CSM may modify neuropeptide expression by immediately increasing the serum concentration of nociception-related biomarkers (oxytocin, neurotensin, orexin A, but not cortisol) in the blood of female subjects with non-specific mechanical neck pain.

Introduction

Neck pain is a common phenomenon and may produce varying degrees of disability. Spinal manipulation (SM) is a common technique for treatment of neck pain and has demonstrated various mechanical, neurophysiologic, and analgesic effects [1]. Females have a greater propensity to develop neck pain as opposed to males [2,3].

In the United States (US), opioid prescriptions to manage spinal pain have increased considerably since the 1990s and are now the most commonly prescribed drug class [4]. Complications from opioids range in severity from constipation, sexual dysfunction, and depression to addiction and overdose-related mortality [4–6]. In 2016, 116 individuals died every day from an opioid-related overdose [7]. Prescription opioid-related overdose deaths were five times higher in 2016 as compared to 1999 [8]. In 2017, the US Department of Health and Human Services declared an opioid-related public health emergency and announced a 5-Point Strategy to Combat the Opioid Crisis [7]. Two of the strategies included expanding research focused on pain management and advancing better practices for pain management [7]. Due to the adverse side effects associated with prescription opioid usage, drug-free pain management strategies such as SM should be more readily considered for individuals with spinal pain [9].

SM is used by physical therapists and other healthcare practitioners as an intervention to help relieve spinal pain and reduce disability [2,3]. SM has been shown to be an effective intervention for patients with non-specific mechanical neck pain (NS-MNP) [10], either alone or in combination with exercises as part of a multimodal management strategy [9,11,12].

The mechanism by which SM modulates pain remains poorly defined; however, there is evidence to suggest that analgesia may occur after SM [13,14]. There are a variety of observed and proposed phenomena that may explain the mechanisms for the psychological, mechanical, or neurophysiological responses from a SM associated with alterations in pain.

KEYWORDS

Spinal manipulation; oxytocin; neurotensin; orexin A; cortisol; neck pain
processing or sympathetic and motor systems' excitation [15,16]. Of these three mechanisms, the neurophysiological mechanism which triggers a cascade of changes in the peripheral and autonomic nervous systems and endocrine system, is the most widely accepted [9]. However, a single session of spinal mobilization or manipulation produces significant yet short-lived neurophysiological effects, typically lasting 5 min or less [17,18]. More recently, there is moderate emerging evidence supporting a modulation of biochemical mechanisms as well, suggesting that a mechanical stimulus provided by SM can trigger changes in analgesic and anti-inflammatory serum markers in asymptomatic individuals [9,19].

A recent study suggested that the mechanical stimulus produced during cervical manipulation seems to increase the serum concentration of neurotensin, oxytocin, and cortisol in asymptomatic subjects [19]. Oxytocin, neurotensin, and orexin A have anti-nociceptive effects while it has been well established that the endocrine-related steroid hormone cortisol serves a role in analgesia as it relates to stress response as well as immune parameters associated with the inflammatory process [9,19–23].

In a recent systematic review and meta-analysis, Kovanur-Sampath K, et al. investigated changes in biochemical markers following SM [9]. The authors defined biochemical markers as any chemical substance that modulates pain or inflammation and were classified into three broad biomarker categories: (1) neuropeptides, (2) inflammatory, and (3) endocrine. Out of the 1217 citations screened, only eight (8) met the inclusion criteria and were included in the final review. Of the eight studies, seven (7) were conducted on pain free, healthy volunteers. The single study, conducted 20 years ago, in subjects with pain was a four group randomized clinical trial with 40 male subjects total with 10 subjects in each group (i.e. pain-free SM, pain SM, pain-free sham, and pain sham) [24]. Their outcome measures were cortisol, adrenocorticotropic hormone (ACTH), and β-endorphin (an agonist of opioid receptors) and no changes in any outcomes were noted.

In light of the well-documented side effects of prescription opioids, drugless therapies such as SM may provide a viable treatment option for individuals in pain [9,25]. It is our understanding that to date, this is the first study to examine the immediate effects of cervical SM on biochemical markers in symptomatic females, the gender with the highest prevalence of cervical spine pain. In addition, this is the first study to investigate the effects on SM on the neuropeptides oxytocin, neurotensin, and orexin A in individuals with cervical pain.

Taking the above-mentioned findings into account, our purpose was to investigate whether cervical spinal manipulation (CSM) would result in a consistent biochemical response or change neuropeptide and cortisol serum concentrations. Therefore, the purpose of this study was to evaluate the immediate effect of CSM on modulation of biochemical markers associated with pain perception and stress response (neurotensin, oxytocin, orexin A, and cortisol). We hypothesized that the mechanical stimuli initiated from a CSM may modulate key analgesic neuropeptide biomarkers in symptomatic female subjects.

Methods

Participants

A total of twenty-eight (28) females between the ages of 20 and 45 years with a primary complaint of NS-MNP were recruited for this study through flyers and word-of-mouth. Thirteen (13) subjects were randomly assigned to the experimental group (CSM) and fifteen (15) subjects to the sham group (sham manipulation). Inclusion criteria included: resting neck pain [as measured by the Numeric Pain Rating Scale (NPRS)] for ≤30 days that is aggravated by movement but does not extend distal to the shoulders and a score ≥10/50 on the Neck Disability Index (NDI) [26–28]. Exclusion criteria were: serious medical conditions (e.g. cancer, spondylolisthesis, rheumatoid arthritis, ankylosing spondylitis, or other related autoimmune disease), cervical myelopathy signs (e.g. incoordination in hands, arms and legs, inability of walking at a brisk pace, bowel and bladder incontinence, etc.), nerve root compression (e.g. changes in sensation, muscle weakness, or decreased reflexes), working the night shift, steroid medication within three months, pregnancy or postpartum, pending legal action regarding their neck pain, history of whiplash associated disorder, neck pain from a traumatic event, and/or cervical spine surgery. All methods and procedures were approved by the Institutional Review Board (IRB) of Loma Linda University prior to commencing the study. This study was registered as a clinical trial at ClinicalTrials.gov Protocol Registration and Results System (#NCT 03176654).

Examination procedures

Since the majority of individuals with cervical spine pain lack an underlying pathology or abnormal anatomical condition, they are frequently classified as NS-MNP [29]. For this study, we have operationally defined NS-MNP as neck pain without traumatic onset with resting pain that is provoked with certain cervical movements and/or postures (aggravating factors) but relieved by moving out of the provocative position and/or postures (easing or ameliorating maneuver). In order to classify subjects with NS-MNP, each
subject received a thorough examination. Subjects provided demographic information, and completed self-reported measures to assess disability, pain, and stress levels at baseline. Self-reported measures included the NDI, NPRS [22,30,31], and Perceived Stress Scale (PSS) [28].

The Neck Disability Index: The NDI is the most widely used condition-specific disability scale for patients with neck pain. It consists of 10 items, 8 items addressing various aspects of function and 2 items addressing impairments (i.e. pain intensity, headaches), each scored from 0 to 5, with a maximum possible score of 50 points. A score of 10/50 is considered a mild disability. The NDI has been reported to be a reliable and valid outcome measure for patients with neck pain [28].

Numeric Pain Rating Scale: The subject’s current resting pain level was established using the NPRS. The NPRS is an 11-point numeric pain intensity rating scale, ranging from 0 (‘no pain’) to 10 (‘worst imaginable pain’) [28]. The NPRS has been shown to be accurate as a screening test to identify primary care patients with clinically important pain. The NPRS exhibits fair to moderate test-retest reliability and has also showed adequate responsiveness in patients with mechanical neck pain. Also, the NPRS has adequate evidence of construct validity including sensitivity for both pain intensity and unpleasantness [22,30].

Perceived Stress Scale: The PSS is standardized widely used psychometric instrument for assessing the perception of stress. It is a measure of the degree to which situations in one’s life are appraised as stressful. The PSS has established internal consistency (Cronbach’s α = 0.87) and good test-retest reliability (ICC = 0.86, p < .001) [28].

Next, the history and subjective examination was conducted. The examination was concluded with a thorough physical examination, when possible, using validated assessment tools [23] and diagnostic reasoning to classify the subject as having NS-MNP and to establish that the subject is appropriate to receive a CSM as well as to screen for potential red flags.

Outcomes measures

The primary outcome measures of this study were peripheral blood serum levels of oxytocin, neuropeptide, orexin A, and cortisol pre- and post-CSM interventions.

Blood sample collection protocol

Blood sample collection

Subjects arrived to their blood sample collection nil per os for 10 h which took place between 8 AM and 11 AM. After the subject was assessed for heart rate, blood pressure and was determined appropriate to receive SM, they were positioned supine on a high low treatment table with a single pillow under their head. Blood oxygenation was measured in the bilateral upper extremities with a pulse oximeter. Venipuncture was performed following standard protocol in the antecubital region of the upper extremity with the highest blood oxygenation using a BD Vacutainer® Safety-Lok™ Blood Collection 23-gauge butterfly needle and collected in serum separator tubes (BD Vacutainer®) by a phlebotomist with 9 years of experience. After needle placement, 6–8 mL of blood was collected in a Serum Separator tube. After the specimen was drawn, the blood collection device was stabilized while the SM or sham SM intervention took place. Care was taken to ensure that the subject was immobile with the exception of the cervical spine and head during the SM or sham SM. Standard blood specimen collection protocol was followed and specimens were promptly mixed after collection. The average time between collection of the pre-and post-blood specimens was 60 s and the average post-intervention collection started 20 s after the SM or sham SM since oxytocin plasma concentration has a half-life of approximately 1.5 min [32]. Prior to collecting post-intervention blood samples (one Serum Separator tube with 6–8 mL of blood) approximately 5 mL of blood were drawn and wasted to clear the blood collection device of pre-intervention blood product.

Blood sample pre-analytics

The Vacutainer tubes stood upright at ambient room temperature (22°C) for one hour before being centrifuged at 1000g for 10 min at 4°C (Allegra® X-ISR, Beckman Coulter, USA). The serum was then aliquoted into multiple snap-cap micro Eppendorf freezer vials and stored at −80°C until analyzed.

Reagents and instrumentation

Study samples were analyzed for human oxytocin, neuropeptide, orexin A, and cortisol using the Milliplex Map Magnetic Bead Panel Immunoassay on the Luminex 200 platform (MilliporeSigma, Burlington, Massachusetts 01803). The Human Neuropeptide Magnetic Bead set (cat. #HNMAG-35K-03 with kit lot #2782901) and Human Circadian/Stress Magnetic Bead set (cat. # HNCSMAG-35K-01 with kit lot #2782855) were purchased from EMD Millipore (Burlington, Massachusetts). Samples were assayed by the clinically certified University of Minnesota Clinical Cytokine Reference Laboratory, Minneapolis, MN (CRL).

Randomization

Following subject assessment and acceptance into the study, subjects were randomly assigned; using
computer-generated randomized sequencing, into either the experimental (CSM) or sham CSM group. Subjects were blinded to the intervention group, however, based on the nature of the intervention; it was not possible to blind the treating therapist.

**Treatment procedure**

Subjects in the experimental group were treated for one session of cervical spine manipulation.

**Cervical spine manipulation protocol and procedure**

A CSM was applied to the site of pain and/or restriction with the patient in supine. This procedure was performed in both the right and left direction, first away from pain then toward pain. This CSM technique uses both primary levers (pre-manipulation rotation away, 30°–45°, from the side of pain or limitation) and secondary levers (side bending toward the side of pain coupled with lateral shift away, and then a posterior-anterior shift) (Figure 1). This is a bimanual technique. For the applicator hand, the anterolateral portion of the first or second phalanx of the second ray was positioned on the superior joint partner of the target vertebrae using a cradle hold. The other hand was placed on the posterolateral aspect of the occiput (above the ear). While maintaining these positions, the clinician performed the high velocity, low amplitude thrust with the arc of rotation dependent on the level of the target vertebrae. Dunning et al. have described the technique used in this study [33].

**Sham protocol**

Subjects in the sham group were instructed to lay on a plinth in the same position as the CSM group. The clinician conducted the same basic steps as the SM, localizing the appropriate vertebral landmarks but without moving the individual or carrying out the final thrust procedure. At the conclusion of the research session, all subjects in the sham group received CSM so as not to withhold an intervention that might be beneficial (without further blood sampling).

We did not experience a single adverse event from cervical spine manipulation in this study, suggesting that the subjects were screened adequately. Each subject experienced multiple cavitations during the thrust manipulation to both the left and the right. The procedures were performed by a physical therapy with 9 years of experience.

**Sample size**

The sample size was estimated using an effect size of 0.9 between the SM and sham group, a power of 0.8, and level of significance $\alpha = 0.05$. The sample size needed was estimated to be 30 (15 in each group).

**Data analysis**

Mean ± SD was computed for quantitative variables and median (min, max) for ordinal variables. Normality of quantitative variables was assessed using Shapiro–Wilk test and box plots. Independent $t$-test was used for all continuous and independent variables in both groups at baseline. Mann–Whitney $U$ test was used for

![Figure 1. Cervical spinal manipulation.](image)
Results

Out of the 30 participants screened, 28 subjects satisfied the eligibility criteria, agreed to participate, and were randomly assigned into the experimental group (n = 13) using a computer-generated random sequencing (Figure 2). Baseline characteristics of participants are shown in Table 1. None of the demographic variables were significant (as expected) for randomized design except for age (mean ± SD: 33.4 ± 7.2 years). This could be due to chance or small sample sizes. Normality assumption of quantitative variables was checked and it was satisfied.

The 2 × 2 mixed factorial ANOVA revealed no significant interaction of treatment by time. The between-group analysis revealed no statistical significance difference between the CSM Intervention & Sham. Therefore, the analysis was reduced to a paired t-test for each variable as it is shown in Table 2.

There was a significant increase in mean oxytocin (p = .012), neurotensin (p < 0.001), and orexin A (p = .005) over time for the intervention groups. However, there was no significant change in sham groups. Lastly, there was no significant difference in mean cortisol (p = .052) for the intervention group or for the sham group (p = .123) (Table 2, Figure 3).

Discussion

To our knowledge, this is the first study to evaluate the effectiveness of CSM on nociception-related biomarkers in females with NS-MNP. Our findings suggest that the mechanical stimuli from the CSM may modify neuropeptide expression in symptomatic subjects by statistically significant increase in the serum concentration of neurotensin, oxytocin, and orexin A in subjects with non-specific mechanical cervical spine pain.

Changes in neuropeptides

The results of the current study suggest that CSM may have an immediate effect in increasing three of the neuropeptides of interest in this study. Although the underlying mechanisms and functional role of SM remain undefined, our post-manipulation data allows us to postulate that the biomechanical force [34] created by SM may be capable of modulating these biomarkers [19].

Oxytocin

Oxytocin is produced within the hypothalamus and stored in Hering bodies of the posterior pituitary [35]. Oxytocin plays an endocrine role in modulating pain by blocking the activity of Aδ and C fibers without effecting non-nociceptive Aβ fibers [36,37]. The findings of this study show a significant increase in mean circulating serum oxytocin, a well-recognized biochemical analgesic, in the CSM group. Our findings were similar to the findings of Plaza-Manzano et al. [19] who reported a significant change in oxytocin following a SM study on asymptomatic individuals but not in the control group. Neuropeptides are released without delay or lag time since the...
Table 2. Between/within group comparison of neuropeptide and cortisol levels.

| Variable      | CSM Intervention (n₁ = 13) | Sham (n₂ = 15) |
|---------------|-----------------------------|----------------|
| Oxytocin §    | 154.5 ± 60.1 185.1 ± 75.6  | 158.8 ± 47.3    |
|               | 30.6 (10.97, 72.63)         | 30.3 (-0.44, 61.05) |
| Neurotensin § | 116.0 ± 26.5 136.4 ± 34.1  | 125.6 ± 30.3    |
|               | 20.42 (11.44, 29.39)        | 6.0 (-8.80, 20.81) |
| Orexin A §    | 52.2 ± 31.1 73.8 ± 38.8    | 62.9 ± 28.5     |
|               | 21.60 (7.75, 35.46)         | 4.48 (-10.29, 19.25) |
| Cortisol ‡    | 9.57 ± 5.80 10.80 ± 7.18   | 12.74 ± 5.86    |
|               | 1.23 (-0.15, 2.48)          | 1.23 (-38, 2.84) |

* p < 0.05.
Values are presented as mean ± SD.
§ Concentration of Oxytocin, Neurotensin, and Orexin A in serum samples (pg/mL).
† Concentration of cortisol in serum samples (ug/dL).
° p-values for the null hypothesis that there is no difference between pre and post.
′ p-values for the null hypothesis that there is no difference between groups (CSM vs. Sham).
CI° = 95% Confidence Interval for difference between pre and post.
CI′ = 95% Confidence Interval for difference between groups (CSM vs. Sham).

Figure 3. Mean and 95% confidence interval error bar for oxytocin, neurotensin, orexin A, cortisol concentration in blood samples.
neurotransmitter response needs to be immediate. Oxytocin plasma concentration has a half-life of approximately 1.5 min [32]. For this reason our second blood draw started within 20 s following the manipulation so that the third blood draw would be complete by 90 s post-manipulation. The second blood draw was drawn and wasted to clear any pre-intervention blood from the device.

**Neurotensin**

The findings of this study show a significant increase in mean circulating serum neurotensin, a well-recognized biochemical analgesic, in the SM group while no significant change was noted in the sham group. This tripeptide neuropeptide is extensively dispersed in the peripheral and central nervous systems [38]. Neurotensin has a wide range of actions, of which the one of greatest interest to this study being that of anti-nociception [39]. The analgesic actions of neurotensin are dissimilar to opioids making it a neurotransmitter of keen interest to pharma since it can be administered systematically or topically for pain management as an opioid alternative [39]. Neurotensin has analgesic impacts which are nalox-one self-regulating and subsequently not reliant on opioids [16]. Neurotensin also affects the activity of the oxytocin-positive cells in the supraoptic nucleus of the hypothalamus [40]. Our findings are similar to those reported by Plaza-Manzano et al. in asymptomatic subjects [19]. To our knowledge, these are the only two studies that have investigated the activation of neurotensin with any form of manual therapy.

**Orexin A**

Of the neuropeptides assessed in this study, orexin A has been studied the least with respect to manual therapy. There is only one prior human study, Plaza-Manzano investigated the release of orexin A with SM in asymptomatic subjects [19]. There is, however, ample evidence that the central nervous system or intravenous administration of orexin A through injection suppresses rheumatoid arthritis-induced hyperalgesia, mechanical allodynia, and thermal hypersensitivity suggesting regulation of nociceptive processing in rats [41–43]. In another rat model, a significant change in orexin A was reported following electroacupuncture (EA) suggesting orexin A involvement in acupuncture analgesia [44]. These findings suggest that much like SM, EA can regulate descending inhibitory systems to achieve analgesic effects through changes in neuropeptide serum concentrations.

Our study has shown a statistically significant change in orexin A following mechanical stress provided by CSM in females with NS-MNP. No significant difference was realized in the sham group. Even though orexin A has been shown to have hypoalgesic properties in rat studies, the first human study assessing the effect of SM on orexin A failed to show any significant difference while significant increases in the neurotensin and oxytocin neuropeptides in asymptomatic individuals were realized [19].

In addition to analgesic actions, in stress situations, orexin A activates glucocorticoid production [45]. In a rat model, injection of orexin elevated corticosterone levels at 15 min and these levels stayed elevated for a minimum of 60 min [46]. The increase in cortisol was dose dependent for orexin [46]. Note: Corticosterone is the primary glucocorticoid in rodents involved in stress responses and immune reactions, which is the equivalent to cortisol in humans. Our findings identified a significant increase in orexin A and no significant difference in cortisol immediately following CSM. Our findings are in line with animal study findings following stimuli [44] and with a recent systematic review reporting moderate evidence in favor of SM influencing neuropeptides and other biochemical markers [9]. Nevertheless, our findings differed from those reported by Plaza-Manzano [19] in regards to orexin A expression.

**Cortisol**

Our findings showed no significant differences in mean cortisol ($p = .052$) serum concentration. It has been well established that the endocrine-related steroid hormone cortisol serves a role in analgesia as it relates to the stress response [9,19–21]. In addition, cortisol is a potent anti-inflammatory and helps one cope with stress [47]. Cervical SM can influence inflammatory and immune biomarkers including cortisol [9,48,49]. Our findings differed from the findings of Plaza-Manzano et al. [19] who reported a significant change in cortisol following a SM study on asymptomatic individuals but not in the control group. One reason for this difference may be because our blood draw occurred immediately following manipulation rather than at delayed time intervals as described by Plaza-Manzano et al [19]. Oxytocin plasma concentration has a half-life of approximately 1.5 min while the half-life of cortisol is approximately 60–90 min [32]. The secretion of cortisol is not immediate and is controlled through one of the three inter-communicating regions of the body, the Hypothalamus-Pituitary-Adrenal (HPA) Axis. Our IRB limited the number of blood draws to three per subject for this study. Neuropeptides and cortisol behaviors are different. An immediate blood draw, necessary to capture neuropeptides, may have been too premature to fully capture changes in cortisol levels. The primary intent of this study was to assess the acute response of neuropeptides to SM.
In a human subject study examining the effect of SM in males on salivary cortisol, μ-endorphin, and ACTH, they found no changes in any outcome measures 5 min and 30 min post-intervention [24]. This is in agreement with the Whelan et al. study that found no changes in basal cortisol levels in healthy males, as assessed through noninvasive salivary samples, at 5 and 60 min following 5-consecutive weeks of cervical SM. Whelan et al. concluded that neither SM nor the anticipation of the SM induces an adequate stress state to alter cortisol levels in asymptomatic subjects [50].

Our study design was similar to the Plaza-Manzano et al. [19] methodology in that both studies used venipuncture to collect serum cortisol levels. The use of venipuncture in itself can increase perceived stress levels and therefore cortisol levels. The use of serum cortisol may not be generalizable to their male counterparts. Another limitation was the use of serum cortisol testing rather than salivary cortisol since venipuncture can increase perceived stress levels and potentially cortisol. However, this study was faced with the same dilemma as Plaza-Mananzano group [19]: The three neuropeptides of interest in our study required venipuncture in order to obtain serum samples. Once the skin was broken to obtain baseline neuropeptide measurements, the post-CSM salivary cortisol testing was no longer viable. Also, the fact that the half-life of oxytocin is very short, as compared to cortisol, the final blood draw concluded within 90 s following the SM may have been too premature for cortisol to cross the HPA axis and enter into the blood stream. Additional blood draws would have been advantageous. Lastly, the diagnostic label of NS-MNP suggests that this entity is a heterogenic condition [29]; however, the findings of the current study may not be generalizable to individuals with known underlying anatomical structures or mechanisms (e.g., cervical spondylosis, herniated disc) responsible for patients’ pain impairments.

**Limitations**

There were numerous limitations in this study. The small sample size was the main limitation. In addition, although there was a sham group, there was a lack of a control group with no touch contact. The vertebral pressure applied during the set-up for the thrust (preload) in the sham group could affect paraspinal proprioceptive mechanisms [52] and, as a result, may alter biomarkers’ concentrations. Another limitation was that there was no minimal pain level established for subjects to be included in the study. To be included in the study, subjects needed to have cervical pain at rest that was aggravated by certain movements or postures, which may be a study limitation. Subjects in the sham group had resting pain as low as 1/10 and in the CSM group as low as 2/10. The mean resting pain level was relatively low for both groups. Even though the subjects matched the operational definition for NS-MNP, they might not match the typical patient seeking physical therapy services. Despite the relatively low NPRS, the median pain rating from Section 1 of the NDI (Pain Intensity) was ‘The pain is moderate at this moment’ for both groups.

This study focused only on the immediate effects of CSM without a short- or long-term follow-up and this is a potential limitation. In addition, since this study was conducted on females with NS-MNP, findings may not be generalizable to their male counterparts. Another limitation was the use of serum cortisol testing rather than salivary cortisol since venipuncture can increase perceived stress levels and potentially cortisol. However, this study was faced with the same dilemma as Plaza-Mananzano group [19]: The three neuropeptides of interest in our study required venipuncture in order to obtain serum samples. Once the skin was broken to obtain baseline neuropeptide measurements, the post-CSM salivary cortisol testing was no longer viable. Also, the fact that the half-life of oxytocin is very short, as compared to cortisol, the final blood draw concluded within 90 s following the SM may have been too premature for cortisol to cross the HPA axis and enter into the blood stream. Additional blood draws would have been advantageous. Lastly, the diagnostic label of NS-MNP suggests that this entity is a heterogenic condition [29]; however, the findings of the current study may not be generalizable to individuals with known underlying anatomical structures or mechanisms (e.g., cervical spondylosis, herniated disc) responsible for patients’ pain impairments.

**Suggestions for future research**

Further studies should consider recruiting a diverse age and gender population. Future studies to compare the concentrations of circulating serum biochemical markers following SM to other forms of manual therapy such as spinal mobilization may be warranted. The dosage needed to cause pain modulation has not been determined. Additional blood draws at longer time intervals are recommended for future studies.
Future research is needed to see if individuals in pain respond to mechanical stimuli differently than healthy controls within the same study. A recent article suggested that research studies using small samples of healthy subjects should give way to randomized controlled trials on subjects with pain [17]. The authors of this study concur and recommend a follow-up study with a larger sample size of symptomatic individuals.

**Conclusion**

The results of the current study suggest that the mechanical stimuli provided through a CSM may modify neuropeptide expression by immediately increasing the serum concentration of neurotensin, oxytocin, and orexin A in the blood of female subjects with NS-MNP. These findings could contribute to the body of knowledge with more information on the effects of CSM and its relationship to neurochemical changes related to stress and pain perception. Furthermore, this study may aid to validate past studies by providing the potential mechanism responsible for the positive physical therapy outcomes related to neck pain and CSM. The findings of this study, combined with the findings of others may support a biochemical-neurophysiological mechanism for pain modulation following CSM.

**Acknowledgments**

The authors thank the Department of Physical Therapy at Loma Linda University for supporting this research. The authors thank Dr. Shwetambari Korde for technical support and Dr. Stacy Yoon for editing assistance.

**Disclosure statement**

No potential conflict of interest was reported by the authors.

**Funding**

This work was supported by the Loma Linda University.

**Notes on contributors**

**Dr. E.B. Lohman** is a Professor and Associate Dean for Graduate Academic Affairs at Loma Linda University (LLU), School of Allied Health Professions (SAHP) as well as the program director of the post-professional physical therapy programs at LLU, SAHP, Department of Physical Therapy. He serves as the orthopaedic track coordinator for the entry-level and post-professional Doctor of Physical Therapy programs. He has been a physical therapist for 29 years. He is the director of a research laboratory and his research interests include orthopaedics and sports-related topics. He has taught orthopaedics and medical screening for 21 years.

**Gabriel Pacheco**, received his Bachelor and Master of Science in Physical Therapy and Kinesiology in 1997 from the National University of Cordoba, Argentina. The same year he started working as an instructor for Clinical Practice at the National Hospital of Cordoba for Physical Therapy and Kinesiology Department for the following seven years. Later in 2012, he continued with his education to earn a Doctor of Science in Physical Therapy at Loma Linda University. During his program, he joined the Department of Physical Therapy at Loma Linda University, Loma Linda, CA where he became an instructor and laboratory assistant for the following subjects: Orthopedic and Medical Screening for the entry-level and post-professional Doctor of Physical Therapy programs for the last five years. His research interests include orthopaedics-related topics.

**Dr. L. Gharibvand** has expertise in epidemiology, health-related research, statistical analysis, biostatistics, survival analysis, experimental designs and clinical trials. She is an assistant professor at Loma Linda University, School of Allied Health Professions. Dr. Gharibvand is teaching courses related to bio/statistics, research methods and data analysis to graduate and undergraduate students from multiple disciplines. Her research interests involve air pollution, public health, geriatrics, DNA Methylation, medical science, and oncology. Dr. Gharibvand is also the president of SAS Users Group in Orange County and Inland Empire and serves on the Leadership Council of American Statistical Association for Orange County & Long Beach Chapter. She holds a PhD degree in Epidemiology from Loma Linda University, Master of Science degree in Applied Statistics from University of California-Riverside, and Master of Science degree in Mathematics from University of Nevada-Reno.

**Dr. N. Daher** is a professor of Statistics and Research at Loma Linda University (LLU), School of Allied Health Professions (SAHP), and an assistant professor of Epidemiology at LLU, School of Public Health. She has been a member of the American Statistical Association since 1995 and a member of the Society for Epidemiologic research since the year 2005. She has taught Statistics, Research, and Epidemiology for 25 years. She has been a statistician for 36 years. Her research interests include nutrition, lifestyle, aging, and exercise topics.

**Ms. K. Devore** is the Clinical Research Coordinator at Loma Linda University (LLU), School of Allied Health Professions (SAHP). She earned her Masters Science degree from the University of California, Riverside. She is also a licensed Phlebotomist for nine years.

**G. Bains** is an Associate Professor for the School of Allied Health at Loma Linda University. He received his PhD from Loma Linda University, MD from Ross University Medical School, and a BSC in Finance from the University of Illinois, Urbana-Champaign. He has been involved in research that includes humor/laughter, intermittent fasting, inflammation, high intensity interval training and weight loss, sleep, blood flow, and spinal pain. Dr. Bains has presented at numerous scientific meetings and his research has gained worldwide media attention such as ABC News Worldwide, CNN, Ellen DeGeneres Show, Men's Journal, Fox News, and Huffington Post.

**M. Alameri** received his education and training from October 6 University and Loma Linda University (LLU). Since graduation, Mansoor has been involved in clinical research and academic work to bridge the gap between biomedical and psychosocial dimensions of musculoskeletal disorders. Mansoor is also a PhD candidate conducting
clinical research at LLU, School of Allied Health Professions (SAHP), Department of Physical Therapy, post-professional Physical Therapy programs.

Dr. L.S. Berk has over 30 years of experience and expertise in the field of psychoneuroimmunology. He is recognized as a “world class” researcher and a pioneer of psychoneuroimmunology with endorphnergic and immune modulation with exercise and, in particular, for his research on positive affect lifestyle behaviors (eustress) with humor-associated mirthful/laughter compared to distress. He is currently the Associate Dean for Research Affairs at Loma Linda University (LLU), School of Allied Health Professions (SAHP). He is also the Director of the Clinical Molecular Research Laboratory, Associate Director of the Cardiovascular and Physical Fitness Lab, Associate Professor at LLU SAHP and School of Medicine and Faculty of Graduate Studies. He is a Research Professor in the Department of Pathology and Human Anatomy in the School of Medicine, LLU. He is a non-resident faculty scholar at the Center for Spirituality, Theology and Health at Duke University. Dr. Berk has been non-resident faculty scholar at the Center for Spirituality, Theology and Health at Duke University. Dr. Berk has been interviewed by numerous news media for his innovative research findings including CBS 60 Minutes, ABC World News Tonight, NBC Good Morning America, National Public Radio, and CNN with Dr. Sanja Gupta, the BBC, Fox TV, WebMD, Australian TV, German TV and other numerous documentary groups national and international.

ORCID
M. AlAmeri http://orcid.org/0000-0002-7986-5765

References

[1] Gross A, Miller J, D’Sylva J, et al. Manipulation or mobilisation for neck pain: a Cochrane review. Manual Ther. 2010;15(4):315–333.

[2] Hoy D, Protanl M, De R, et al. The epidemiology of neck pain. Best Pract Res Clin Rheumatol. 2010;24(6):783–792.

[3] Raghavendra MHJ. Gender differences in the prevalence of cervical degenerative disc disease. American Academy of Pain Management Annual Meeting. 2016. [Accessed October 31, 2018]. Available from: http://www.painmed.org/2016/posters/abstract-186/

[4] Deyo RA, Von Korff M, Duhrkood D. Opioids for low back pain. Bmj. 2015;350:g6380.

[5] Kenneth D, Kochanek MA, Sherry L, et al. Mortality in the United States. 2016. [Accessed 2017]. Available from: https://www.cdc.gov/nchs/data/databriefs/db293.pdf

[6] Abuse NIoD. National Survey of Drug Use and Health. 2016.

[7] U.S. Department of Health and Human Services. What is the U.S. opioid epidemic? 2018. [Accessed October 31, 2018]. Available from: https://www.hhs.gov/opioids/about-the-epidemic/index.html

[8] Seth P, Rudd RA, Noonan RK, et al. Quantifying the epidemic of prescription opioid overdose deaths. American Public Health Association. 2018.

[9] Kovanur-Sampath K, Mani R, Cotter J, et al. Changes in biochemical markers following spinal manipulation—a systematic review and meta-analysis. Musculoskeletal Sci Pract. 2017;29:120–131.

[10] Hidalgo B, Hall T, Bossert J, et al. The efficacy of manual therapy and exercise for treating non-specific neck pain: a systematic review. J Back Musculoskelet Rehabil. 2017;30(6):1149–1169.

[11] Bronfort G, Haas M, Evans R, et al. Effectiveness of manual therapies: the UK evidence report. Chiropr Osteopat. 2010;18(1):3.

[12] Gross AR, Hoving JL, Haines TA, et al. A Cochrane review of manipulation and mobilization for mechanical neck disorders. Spine (Phila Pa 1976). 2004;29(14):1541–1548.

[13] Carraway R, Leeman SE. The isolation of a new hypotensive peptide, neurtensin, from bovine hypothalamus. J Biol Chem. 1973;248(19):6854–6861.

[14] Dorron SL, Losco BE, Drummond PD, et al. Effect of lumbar spinal manipulation on local and remote pressure pain threshold and pinprick sensitivity in asymptomatic individuals: a randomised trial. Chiropr Man Therap. 2016;24(1):47.

[15] Lénard L, László K, Kertes E, et al. Substance P and neurtensin in the limbic system: their roles in reinforcement and memory consolidation. Neurosci Biobehav Rev. 2017;85:1–20.

[16] Clineschmidt BV, McGuffin JC, Bunting PB. Neurtensin: antinocicpsive action in rodents. Eur J Pharmacol. 1979;54(1–2):129–139.

[17] Hegedus EJ, Goode A, Butler RJ, et al. The neurophysiological effects of a single session of spinal joint mobilization: does the effect last? J Man Manip Ther. 2011;19(3):143–151.

[18] Coronado RA, Gay CW, Bialosky JE, et al. Changes in pain sensitivity following spinal manipulation: a systematic review and meta-analysis. J Electromyogr Kinesiol. 2012;22(5):752–767.

[19] Plaza-Manzano G, Molina F, Lomas-Vega R, et al. Changes in biochemical markers of pain perception and stress response after spinal manipulation. J Orthop Sports Phys Ther. 2014;44(4):231–239.

[20] Bassett J, Marshall P, Spillane R. The physiological measurement of acute stress (public speaking) in bank employees. Int J Psychophysiol. 1987;5(4):265–273.

[21] Matousek RH, Dobkin PL, Pruessner J. Cortisol as a marker for improvement in mindfulness-based stress reduction. Complement Ther Clin Pract. 2014;20(5):1–7.

[22] Jensen MP, Miller L, Fisher LD. Assessment of pain during medical procedures: a comparison of three scales. Clin J Pain. 1998;14(4):343–349.

[23] Audette I, Dumas J-P, Côté JN, et al. Validity and between-day reliability of the cervical range of motion (CROM) device. J Orthop Sports Phys Ther. 2010;40(5):318–323.

[24] Christian GF, Stanton GJ, Sissons D, et al. Immunoreactive ACTH, beta-endorphin, and cortisol levels in plasma following spinal manipulative therapy. Spine (Phila Pa 1976). 1988;13(12):1411–1417.

[25] Ballantyne JC, Shin NS. Efficacy of opioids for chronic pain: a review of the evidence. Clin J Pain. 2008;24(6):469–478.

[26] Hains F, Waalen J, Mior S. Psychometric properties of the neck disability index. J Manipulative Physiol Ther. 1998;21(2):75–80.

[27] Riddle DL, Strafford PW. Use of generic versus region-specific functional status measures on patients
with cervical spine disorders. Phys Ther. 1998;78 (9):951–963.
[28] Vernon H, Mior S. The neck disability index: a study of reliability and validity. J Manipulative Physiol Ther. 1991;14(7):409–415.
[29] Tsakitzidis G, Remmen R, Dankaerts W, et al. Non-specific neck pain and evidence-based practice. Eur Sci J. 2013;9:3.
[30] Ferraz MB, Quaresma M, Aquino L, et al. Reliability of pain scales in the assessment of literate and illiterate patients with rheumatoid arthritis. J Rheumatol. 1990;17(8):1022–1024.
[31] Jensen MP, Karoly P, O’Riordan EF, et al. The subjective experience of acute pain. An assessment of the utility of 10 indices. Clin J Pain. 1989;5(2):153–159.
[32] Leng G, Sabatier N. Measuring oxytocin and vasopresin: bioassays, immunoassays and random numbers. J Neuroendocrinol. 2016;28:10.
[33] Dunning JR. American academy of manipulative therapy & spinal manipulation institute. 2014. [Accessed November 01, 2018]. Available from: https://spinalmanipulation.org/
[34] Pickar JG. Neurophysiological effects of spinal manipulation. Spine J. 2002;2(5):357–371.
[35] Standring S, Ellis H, Healy J, et al. Gray’s anatomy: the anatomical basis of clinical practice. Am J Neuroradiol. 2005;26(10):2703.
[36] Uvnäs-Moberg K, Bruzelius G, Alster P, et al. Oxytocin increases and a specific oxytocin antagonist decreases pain threshold in male rats. Acta Physiol Scand. 1992;144(4):487–488.
[37] Rojas-Piloni G, López-Hidalgo M, Martínez-Lorenzana G, et al. GABA-mediated oxytocinergic inhibition in dorsal horn neurons by hypothalamic paraventricular nucleus stimulation. Brain Res. 2007;1137:69–77.
[38] St-Gelais F, Jomphe C, Trudeau L-É. The role of neurotensin in central nervous system pathophysiology: what is the evidence?. J Psychiatry Neurosci. 2006;31(4):229–245.
[39] Rossi GC, Matulonis JE, Richelson E, et al. Systemically and topically active antinociceptive neurotensin compounds. J Pharmacol Exp Ther. 2010;334(3):1075–1079.
[40] Furutani N, Hondo M, Kagayama H, et al. Neurotensin co-expressed in orexin-producing neurons in the lateral hypothalamus plays an important role in regulation of sleep/wakefulness states. PloS one. 2013;8(4):e62391.
[41] Bingham S, Davey P, Babbs A, et al. Orexin-A, an hypothalamic peptide with analgesic properties. Pain. 2001;92(1–2):81–90.
[42] Yamamoto T, Nozaki-Taguchi N, Chiba T. Analgesic effect of intrathecally administered orexin-A in the rat formalin test and in the rat hot plate test. Br J Pharmacol. 2002;137(2):170–176.
[43] Mohamed AR, El-Hadidy WF. Effect of orexin-A (hypocretin-1) on hyperalgesic and cachectic manifestations of experimentally induced rheumatoid arthritis in rats. Can J Physiol Pharmacol. 2014;92(10):813–820.
[44] Feng X-M, Mi W-L, Xia F, et al. Involvement of spinal orexin A in the electroacupuncture analgesia in a rat model of post-laparotomy pain. BMC Complement Altern Med. 2012;12(1):225.
[45] Brennan PC, Kokjohn K, Kaltingham CJ, et al. Enhanced phagocytic cell respiratory burst induced by spinal manipulation: potential role of substance P. J Manipulative Physiol Ther. 1991;14(7):399–408.
[46] Ida T, Nakahara K, Murakami T, et al. Possible involvement of orexin in the stress reaction in rats. Biochem Biophys Res Commun. 2000;270(1):318–323.
[47] Hannibal KE, Bishop MD. Chronic stress, cortisol dysfunction, and pain: a psychoneuroendocrine rationale for stress management in pain rehabilitation. Phys Ther. 2014;94(12):1816–1825.
[48] Teodorczyk-Injeyan JA, Injeyan HS, Ruegg R. Spinal manipulative therapy reduces inflammatory cytokines but not substance P production in normal subjects. J Manipulative Physiol Ther. 2006;29(1):14–21.
[49] Teodorczyk-Injeyan JA, McGregor M, Ruegg R, et al. Interleukin 2-regulated in vitro antibody production following a single spinal manipulative treatment in normal subjects. Chiropr Osteopat. 2010;18(1):26.
[50] Whelan TL, Dishman JD, Burke J, et al. The effect of chiropractic manipulation on salivary cortisol levels. J Manipulative Physiol Ther. 2002;25(3):149–153.
[51] Mirick DK, Bhatti P, Chen C, et al. Night shift work and levels of 6-sulfatoxymelatonin and cortisol in men. Cancer Epidemiol Prev Biomarkers. 2013;22:1079–1087.
[52] Pickar JG, Wheeler JD. Response of muscle proprioceptors to spinal manipulative-like loads in the anesthetized cat. J Manipulative Physiol Ther. 2001;24(1):2–11.